Advertisement

Topics

Companies Related to "A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy" [Most Relevant Company Matches] - Page: 3 RSS

10:57 EST 13th November 2018 | BioPortfolio

Here are the most relevant search results for "A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy" found in our extensive corporate database of over 50,000 company records.

Showing "Phase Randomized Double blind Placebo Controlled Dose Ranging" Companies 51–75 of 1,800+

Relevant

Pennsylvania Association for the Blind


Delcath Systems, Inc.

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of pri...

Citation Clinical Labeling Systems

Over two decades ago we were swifter than anyone else in supplying the Revlon Healthcare with the first fully glued pocket double blind label. Fact is, no other label company was even willing to come up with a quote for the form, much less manufacture it.Today, Citation Clinical Labeling Systems continues to rush quality products and services to the pharmaceutical and biotech industries faster tha...


Recro Gainesville, LLC

Recro Gainesville provides solid dosage form development, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. Specializing in extended release solid dose and DEA controlled substances, Recro has the experts to deliver clients’ most complex pharmaceutical development and manufacturing project...

Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune response to cancer that involves both the innate and adaptive immune system. Proof of concept has been established from single-arm and randomized phase 2 studies in non-small cell...

The E. Matilda Ziegler Foundation for the Blind, Inc.

National Federation of the Blind of California

Unidose Systems Corporation

Unidose Systems Corporation (formerly known as Swabplus Inc.) is the leading manufacturer and inventor of the single-dose cotton-tipped applicator, designed to make consumers' lives easier, more convenient, neater, healthier, and happier. With products ranging from health-care/pharmaceuticals to cleansers to beauty care to dental care to pet care, Unidose Systems Corporation has a vast array of so...

Jennerex Biotherapeutics

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse a...

Blind & Vision Rehabilitation Services of Pittsburgh

Asymptote Ltd

Asymptote is a leading specialist in controlled solidification research and product development, based in Cambridge, UK. Our expertise in freezing and crystallisation covers a wide variety of applications including cryopreservation, food and drink manufacture, freeze drying and scale control.Our products and process technology are tailored to meet our users’ requirements and have resulted in si...

Glide Pharma

Glide Pharma is a specialty pharmaceutical company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines. The company has a range of in-house and partnered programmes based on its proprietary needle-free solid dose injector, the Glide SDI(R).

Double Helix Consulting

Double Helix Consulting US

Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in tri...

Depomed, Inc.

Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Produ...

Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in t...

RheoGene Inc

RheoGene is developing the RheoSwitch® Therapeutic System (RTS) for cell and gene therapy. RTS delivers therapeutic gene products in the patient to the right place, at the right time, and at the right dose. Despite advances in the understanding of the genetic and molecular basis of disease, there are no approved gene therapy products on the market today, in part because of the unmet need for effi...

Biothera Pharmaceutical Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a late clinical stage immunotherapeutic drug candidate that modulates key immune cells to recognize and kill cancer. Proof of concept has been established from single-arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymp...

UltraVolt, Inc

UltraVolt, Inc., located in Ronkonkoma on Long Island, NY was founded in 1990 to take advantage of over 35 years of experience in the military and aerospace marketplace. The founders combine innovative entrepreneurial skills with extensive experience in high voltage power supply design and manufacturing. In its planning phase, UltraVolt completed a comprehensive market survey of over 80 industries...

Phase One Medical, L.L.C.

Phase One Medical is a privately held medical device research and development company. The company is focused on early stage development and small part design and manufacture. For more information on Phase One Medical, L.L.C. products and services e-mail the company at info@phase-one.us.

Ipsen Biopharmaceuticals, Inc.

*MAS responders week 4: 74% to Dysport® 500 units, 79% to Dysport® 1000 units and 23% to placebo

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charco...

BioTime, Inc. and Asterias Biotherapeutics, Inc.

Asterias Biotherapeutics, Inc. is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary, industry leading platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is focused on developing therapies to treat conditions in several medical areas where ther...

Retina Implant AG

Retina Implant, AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals which began in 1996, Retina Implant, AG was founded by Dr. Eberhart Zrenner and his colleagues in 2003 with the goal of developing the first fully-functioning electronic retinal prosthesis to...


More From BioPortfolio on "A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks